文献速递术前评估与围术期医学疼痛医学

围术期艾司氯胺酮输注对胸腔镜肺切除术后慢性疼痛的影响:多中心随机双盲临床试验

Effects of perioperative esketamine infusion on chronic pain after video-assisted thoracoscopic lung resection: a multicentre, randomised, double-blind clinical trial.
PubMed 文献 · Br J Anaesth · 2026-10-28

本研究为多中心随机双盲试验,纳入914例成人胸腔镜肺切除术患者,比较围术期低剂量艾司氯胺酮与生理盐水对术后3个月慢性疼痛的影响。结果显示艾司氯胺酮组3个月慢性疼痛发生率显著低于对照组(14.7% vs 21.2%),且不增加不良事件。

要点

  • 围术期低剂量艾司氯胺酮可降低胸腔镜肺切除术后3个月慢性疼痛发生率。
  • 艾司氯胺酮减少术后48小时内静息及咳嗽疼痛评分和 supplemental 镇痛药需求。
  • 艾司氯胺酮未增加不良事件及药物相关副作用。

核心结论

  • 围术期低剂量艾司氯胺酮输注显著降低胸腔镜肺切除术后3个月慢性疼痛,且不增加不良事件。

研究设计与样本

  • 多中心、随机、双盲、对照临床试验,914例成人随机1:1接受艾司氯胺酮或生理盐水,最终分析873例(中位年龄55岁,女性63%)。

主要发现

  • 艾司氯胺酮组3个月慢性疼痛(咳嗽时数字评分量表≥1)发生率为14.7%,对照组为21.2%(调整OR=0.62,95%CI 0.43-0.90,P=0.013)。
  • 事后定义咳嗽时数字评分量表≥3的3个月疼痛,调整OR=0.39(95%CI 0.19-0.84,P=0.015)。
  • 艾司氯胺酮降低术后48小时内静息和咳嗽总体疼痛评分,并减少48小时内及3个月内 supplemental 镇痛药需求。

关键数值与推荐

  • 艾司氯胺酮用法:诱导时0.1 mg kg-1 单次注射,术中持续输注0.1 mg kg-1 h-1,术后输注0.015 mg kg-1 h-1 持续48小时。
  • 主要结局:术后3个月慢性疼痛,定义为手术区域咳嗽时数字评分量表评分≥1的持续性疼痛。

临床怎么用

  • 对于胸腔镜肺切除术患者,可考虑围术期低剂量艾司氯胺酮输注以降低慢性疼痛风险。
  • 需按本研究方案给药:诱导0.1 mg kg-1,术中0.1 mg kg-1 h-1,术后0.015 mg kg-1 h-1 持续48小时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic postsurgical pain after thoracoscopic surgery remains common. We investigated whether perioperative low-dose esketamine infusion would reduce chronic pain after video-assisted thoracoscopic lung resection. METHODS: In this multicentre, randomised controlled trial, 914 adults were randomly assigned (1:1) to receive either esketamine or normal saline. Esketamine was administered as a 0.1 mg kg-1 bolus at induction, followed by continuous intraoperative infusion (0.1 mg kg-1 h-1) and postoperative infusion (0.015 mg kg-1 h-1) for 48 h. The primary outcome was chronic pain at 3 months, defined as persistent pain with a numeric rating scale score ≥1 during coughing in the surgical region. Secondary outcomes included postoperative pain, supplemental analgesics use, recovery of bowel function, in-hospital adverse events, and esketamine-related side-effects. RESULTS: We analysed 873 patients (median age, 55 yr; 63% female). The incidence of 3 month chronic pain was lower in the esketamine group than in the control group (14.7% vs 21.2%; adjusted odds ratio, 0.62; 95% confidence interval, 0.43-0.90; P=0.013). A reduction was also observed when using a post hoc outcome definition of a numeric rating scale pain score ≥3 during coughing at 3 months (adjusted odds ratio, 0.39; 95% confidence interval, 0.19-0.84; P=0.015). Esketamine also reduced overall pain scores at rest and during coughing within the first 48 h, and decreased supplemental analgesic requirements within 48 h and 3 months. CONCLUSIONS: Perioperative low-dose esketamine infusion significantly reduced 3 month chronic pain after thoracoscopic lung resection without increasing adverse effects. CLINICAL TRIAL REGISTRATION: ChiCTR2000040012. TRIAL REGISTRATION: This trial was registered on the Chinese Clinical Trial Registry (Identifier: ChiCTR2000040012; principal investigator: Fu-hai Ji; dated November 18, 2020; https://www.chictr.org.cn/showprojEN.html?proj=62319).

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Wang, Zhang, Gu, et al. Effects of perioperative esketamine infusion on chronic pain after video-assisted thoracoscopic lung resection: a multicentre, randomised, double-blind clinical trial. Br J Anaesth. 2026. PMID: 42951789. doi:10.1016/j.bja.2026.08.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。